Article Text

Download PDFPDF

2022-RA-1474-ESGO Traditional systemic treatment options in advance low grade serous ovarian cancer after successful cytoreduction. A systematic review and meta-analysis
  1. Rosa Montero Macías1,
  2. Pascal Rigolet2,
  3. Elie Mikhael1,
  4. Jonathan Krell3,
  5. Vincent Villefranque1,
  6. Fabrice Lecuru4 and
  7. Christina Fotopoulou5
  1. 1Gynecologic and Obstetrics Department, Simone Veil Hospital, Eaubonne, France
  2. 2Université Paris-Saclay, Institut Curie, CNRS UMR 9187, Inserm U1196, Orsay, France, France
  3. 3Department of Medical Oncology, Imperial College London, Faculty of Medicine, London, UK, UK
  4. 4Breast, Gynecology and Reconstructive Surgery Unit. Curie Institute., Paris, France, France
  5. 5Department of Gynaecologic Oncology, Imperial College London, Faculty of Medicine, London, UK, UK


Introduction/Background We performed a systematic literature review and a subsequent meta-analysis to compare traditional ie. antihormonal and cytotoxic treatment options in advance Low Grade Serous Ovarian Cancer (LGSOC).

Methodology We conducted a systematic literature review in MEDBASE and MEDLINE between September 2000 and June 2021 for women who received cytotoxic chemotherapy and/or antihormonal treatment after primary cytoreduction due to stage II-IV LGSOC and also at relapse. PFS and OS were calculated depending on the type of their adjuvant treatment. For each endpoint in the meta-analysis, pooled HR was calculated using the random effect model with the inverse variance weighted method. Only primary patients were included in the subsequent meta-analysis due to the small number of studies in the relapsed setting.

Results Five eligible 1st line studies were included. Systemic chemotherapy failed to provide a significant OS benefit when compared to no systemic treatment (pooled HR = 1.01, 95% CI [0.79, 1.29]) after successful cytoreduction.Moreover, systemic chemotherapy followed by antihormonal treatment also did not result to a significant PFS or OS benefit when compared to systemic chemotherapy alone (for PSF: pooled HR=0.59, 95% CI [0.33, 1.04]; for OS: pooled HR=0.83, 95% CI [0.50–1.39]).There were insufficient data from studies in the recurrent setting to allow their inclusion in the meta-analysis.

Abstract 2022-RA-1474-ESGO Figure 1

Conclusion In this meta-analysis, we failed to identify a traditional cytotoxic or antihormonal systemic treatment option that was associated with a significant OS or PFS benefit when administered following successful cytoreduction for advanced LGSOC. Prospective randomised studies are urgently warranted to define optimal adjuvant options in this challenging disease.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.